On 29 March, United Neuroscience, a clinical-stage biotechnology company developing active immunotherapeutics to treat and prevent brain disorders, presented results from the Phase IIa study of UB-311 in Alzheimer’s disease (AD) at the 14th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon (Portugal). The Phase IIa trial is a randomised, double-blind, placebo-controlled, parallel-group and multicentre study to evaluate the safety, tolerability, immunogenicity and efficacy of two doses of UB-311 in people with mild AD. UB-311 is a novel synthetic peptide vaccine targeting beta-amyloid.
43 participants from 60 to 90 years old with mild AD dementia (CDR 0.5 or 1, MMSE 20-26) were enrolled in the study. Except 2 early terminated subjects, all participants completed final assessments at week 78. The vaccine candidate was found to be safe and well-tolerated. Participants of this trial are now eligible to join a long-term extension study that will continue to evaluate the safety and efficacy of UB-311 for 108 weeks.